Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19(T2)28z1xx TRAC T cell
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**19(T2)28z1xx TRAC T cells** are autologous chimeric antigen receptor (CAR)-T cells engineered to target CD19-expressing B-cell malignancies. These cells are created by integrating a CD19-targeted CAR construct into the T-cell receptor alpha constant (TRAC) locus of patient-derived T-cells. The construct features a modified signaling domain with only one functional immunoreceptor tyrosine-based activation motif (ITAM), termed "1XX," which is designed to calibrate activation potential and reduce toxicity compared to traditional constructs with three ITAMs. This modification aims to enhance efficacy, persistence, and safety by reducing the risk of severe cytokine release syndrome and neurotoxicity while maintaining potent anti-tumor activity. The therapy is under investigation primarily for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with early clinical trials showing promising response rates and durability of remission[4][5][6].
- Other names
- TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells
02
Targets
Beyond the preview
Go deeper on 19(T2)28z1xx TRAC T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 19(T2)28z1xx TRAC T cell.